Company / Cash & Equivalents
Mirum Pharmaceuticals, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$296.7M
FY2025
5-year range
$28.0M / $296.7M
FY2021-FY2025
Trend
+33.3%
vs FY2024
Sector context
#63 of 207
Health Care
What the data says
At $297M, Mirum Pharmaceuticals, Inc.'s cash & equivalents ranks #63 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 8 years, ranging from $12M in FY2019 to $297M in FY2025.
Based on SEC 10-K filings.
$297M in FY2025 with a 5-year CAGR of +15.9%.
Improved from $286M to $297M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +119.6%
- 5-Year CAGR
- +15.9%
- 10-Year CAGR
- -
Sector benchmark
#63 of 207 in Health CareTop 30% of 207This company $296.7M Sector average $669.5M
▼
-55.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 33.3% year-over-year.
- Ranks #63 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $296.7M | +33.3% |
| FY2024 | $222.5M | -22.3% |
| FY2023 | $286.3M | +922.5% |
| FY2022 | $28.0M | -10.6% |
| FY2021 | $31.3M | -77.9% |
| FY2020 | $142.1M | +1087.0% |
| FY2019 | $12.0M | -77.0% |
| FY2018 | $52.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026